We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Parallel Tracking i-biomarkerT Development with Drug Development for Maximum Benefit
Video

Parallel Tracking i-biomarkerT Development with Drug Development for Maximum Benefit

Parallel Tracking i-biomarkerT Development with Drug Development for Maximum Benefit
Video

Parallel Tracking i-biomarkerT Development with Drug Development for Maximum Benefit

Molecular imaging is increasingly being used to support decision-making in early-stage drug development, particularly in the CNS. Providing invaluable information on the so-called ‘three pillars of drug survival’, namely tissue delivery, target engagement and pharmacological effect, it can be seen as a kind of precision pharmacology However, a lack of appreciation of when and how to use imaging and a lack of suitable tools means imaging is often an afterthought and employed in a post-mortem of drug failure. Timely development of imaging biomarkers will ensure the full translational value of this technology can be realised 
Advertisement